Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment.
D000038:Abscess / Q000188:drug therapy; D001941:Breast Diseases / Q000188:drug therapy; D003371:Cough / Q000188:drug therapy; D004338:Drug Combinations / Q000009:adverse effects; D004912:Erythrocytes / Q000378:metabolism; D004913:Erythrocytes, Abnormal / Q000473:pathology*; D005260:Female; D005492:Folic Acid / Q000378:metabolism; D005493:Folic Acid Antagonists / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008534:Megaloblasts / Q000473:pathology*; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D010198:Pancytopenia / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D013420:Sulfamethoxazole / Q000009:adverse effects; D014295:Trimethoprim / Q000009:adverse effects; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D005493:Folic Acid Antagonists; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D005492:Folic Acid; D014295:Trimethoprim; D013420:Sulfamethoxazole; D002955:Leucovorin; D008727:Methotrexate